Ascendis Pharma A/S (ADR)

Factors to consider:

• Total employees count: 55 as of 2014
• Price in estimated range

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

• 2025-12-31 to 2026-12-31 estimated range: [129.39$, 266.74$]
• 2026-12-31 to 2027-12-31 estimated range: [103.66$, 222.14$]

Financial Metrics affecting the ASND estimates:

• Negative: with PPE of -47.2 at the end of fiscal year the price was very high
• Negative: negative Operating income
• Positive: Investing cash flow per share per price, % of -0.08 > -0.63
• Positive: 0.01 < Operating cash flow per share per price, % of 0.48
• Positive: Interest expense per share per price, % of 0.72 <= 0.73
• Negative: Shareholder equity ratio, % of -12.50 <= 19.40